A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE)

1. Incidence of treatment-emergent adverse events (TEAEs) during the study 2. Incidence of serious treatment-emergent adverse events during the study 3. Incidence of treatment-emergent adverse events (TEAEs) leading to permanent dapirolizumab pegol discontinuation

1. Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 24, 2. Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 52, 3. Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 104, 4. Achievement of LLDAS at ≥50% of all visits, 5. Achievement of BICLA response at Week 24, 6. Achievement of BICLA response at Week 52, 7. Achievement of BICLA response at Week 104

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Belgium, Bulgaria, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Romania, Spain